Results 61 to 70 of about 17,638 (200)

A guide to transcriptional cyclin‐dependent kinases in cancer

open access: yesThe FEBS Journal, EarlyView.
Transcriptional cyclin‐dependent‐kinases (tCDKs) facilitate gene expression by promoting RNA polymerase II (RNAPII) progression through discrete phases of the transcription cycle. Aberrant tCDK activity is detectable in different human cancers, thereby contributing to de‐regulated gene expression programs that drive oncogenic phenotypes.
Jennifer R. Devlin   +2 more
wiley   +1 more source

Topoisomerase I inhibitors, shikonin and topotecan, inhibit growth and induce apoptosis of glioma cells and glioma stem cells.

open access: yesPLoS ONE, 2013
Gliomas, the most malignant form of brain tumors, contain a small subpopulation of glioma stem cells (GSCs) that are implicated in therapeutic resistance and tumor recurrence.
Feng-Lei Zhang   +6 more
doaj   +1 more source

Scaling temporal resolution from mice to humans: Challenges and innovations in preclinical imaging of translational models

open access: yesThe Journal of Physiology, EarlyView.
Abstract figure legend Temporal scaling physiology differs significantly between mice and humans. Mice have higher metabolism, heart and respiratory rate, as well as faster blood flow rates, brain activity and physiological dynamics over time. These differences influence the temporal resolution needed in preclinical imaging of mouse models to ...
Sara Gargiulo, Matteo Gramanzini
wiley   +1 more source

Topotecan for ovarian cancer [PDF]

open access: yesCochrane Database of Systematic Reviews, 2008
Chemotherapeutic agents such as topotecan can be used to treat ovarian cancer. The effects of using topotecan as a therapeutic agent have not been previously been systematically reviewed.To systematically evaluate the effectiveness and safety of topotecan for the treatment of ovarian cancer.We searched the Cochrane Central Register of Controlled Trials
Minawaer Abudou   +3 more
openaire   +2 more sources

Optimization of liposomal topotecan for use in treating neuroblastoma [PDF]

open access: yes, 2017
The purpose of this work was to develop an optimized liposomal formulation of topotecan for use in the treatment of patients with neuroblastoma. Drug exposure time studies were used to determine that topotecan (Hycamtin) exhibited great cytotoxic ...
Gilabert-Oriol, R   +5 more
core   +1 more source

A simulated trial with reinforcement learning for the efficacy of Irinotecan and Ifosfamide versus Topotecan in relapsed, extensive stage small cell lung cancer

open access: yesBMC Cancer
Objectives Synthetic data may proxy clinical data. At the absence of direct clinical data, this study aimed to compare Irinotecan and Ifosfamide (II) with Topotecan in synthetic, recurrent small cell lung cancer (SCLC) patients within a simulated ...
Hakan Şat Bozcuk, Mehmet Artaç
doaj   +1 more source

Molecular signatures of xenograft colorectal cancer in mice treated with topotecan: A mass spectrometry-based study

open access: yesToxicology Reports
Background: Colorectal cancer (CRC) is one of the most common cancers worldwide, yet it continues to have a low survival rate, largely due to the lack of effective treatments.
Yousra A. Hagyousif   +14 more
doaj   +1 more source

Schedule-Dependent Antiangiogenic and Cytotoxic Effects of Chemotherapy on Vascular Endothelial and Retinoblastoma Cells. [PDF]

open access: yesPLoS ONE, 2016
Current treatment of retinoblastoma involves using the maximum dose of chemotherapy that induces tumor control and is tolerated by patients. The impact of dose and schedule on the cytotoxicity of chemotherapy has not been studied.
Ursula Winter   +9 more
doaj   +1 more source

Infant Embryonal CNS Tumors: Molecular Insights and Treatment Considerations for Contemporary Pediatric Neuro‐Oncology

open access: yesPediatric Blood &Cancer, Volume 73, Issue 11, November 2026.
ABSTRACT Background Embryonal tumors comprise the majority of malignant central nervous system (CNS) neoplasms diagnosed in children under 3 years of age. Compared with their counterparts in older children, these tumors exhibit distinct molecular biology and a more aggressive clinical phenotype, while their management is complicated by the heightened ...
Sudarshawn Damodharan   +3 more
wiley   +1 more source

Preclinical pharmacology and clinical uses of topotecan

open access: yes, 1999
Topotecan, a soluble semisynthetic derivative of camptothecin, is a specific inhibitor of topoisomerase I and is endowed of potent antiproliferative effect in vitro and in vivo on tumoral cell lines as well as on endothelial cells. Moreover, topotecan is
DEL TACCA M   +2 more
core   +3 more sources

Home - About - Disclaimer - Privacy